Enterprise Value to EBITDA Ratio: OS Therapies Incorporated (OSTX)
The prospects for OS Therapies Incorporated (OSTX) depend on the upcoming results of osteosarcoma therapy trials, with the model's risks already priced in. The development of new molecules is accelerating through AI and automation, although final tests require medical participation. The price action history on GURU.Markets with the 0.00 metric confirms the status of a biotech in the R&D stage, which burns capital without operating profit or stable cash flow.
OSTX (ostherapies.com): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock exchange capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity OS Therapies Incorporated|OSTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity OS Therapies|OSTX - Company Total Debt Obligations|Debt to Book Value OS Therapies, Inc.|OSTX - Company Long-Term Loans and Borrowings|Company Current Liabilities OS Therapies|Quick Ratio ostherapies.com
- business earnings and investment ratios data:
OSTX - Final Profit|Projected Future Earnings OS Therapies Incorporated|OSTX - Market Cap to Earnings|Future Price to Earnings OS Therapies Incorporated|OSTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple OS Therapies, Inc.|OSTX - Operating profit EBITDA|Earnings per share for the last twelve months OS Therapies|OSTX - Earnings per one share for the last 12 months|Quarterly EPS earnings growth ostherapies.com|OSTX - Expected net earnings per share growth this year|Earnings growth forecast for next year OS Therapies Incorporated
Comprehensive company analysis:OS Therapies Inc (OSTX)
OS Therapies Incorporated (OSTX) utilizes a unique biotech platform based on modified bacteria, possessing exceptional market influence within the inelastic demand segment for osteosarcoma treatment. The enterprise value to operating profit ratio, reflected in the company's historical EV/EBITDA chart, allows for a real-time assessment of asset value net of debt, revealing either an undervaluation or the risk of capital stagnation in the absence of revenue.
Key competitors
EV/EBITDA Multiple ONC (BeiGene Corp)|HALO - Enterprise Value to EBITDA Ratio|RVMD: Enterprise Value to EBITDA Ratio|AAPG - EV/EBITDA Multiple|CG Oncology (CGON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UroGen Pharma Ltd - Business Value to Operating Income Before Depreciation|BCAX (Bicara Bio) - EV/EBITDA Multiple|Company Value to EBITDA Personalis Genomics PSNL|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Erasca, Inc. (ERAS)|DCTH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Y-mAbs Therapeutics, Inc. YMAB|Total Company Value to Operating Income Before Depreciation Ratio Aura Biosciences Inc (AURA)|CADL: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ARAY (Accuray, Inc.)|SLS (sellaslifesciences.com) - Enterprise Value to EBITDA Ratio|ACTU: Enterprise Value to Operating Income Before Depreciation Ratio|CTOR (Citius Oncology) - EV/EBITDA Multiple|HURA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TARA|FATE - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aadi Bioscience WHWK|Business Value to Operating Income Before Depreciation TCRX|Champions Oncology Corp - EV/EBITDA Multiple|XBIT - EV/EBITDA Multiple|cel-sci.com (CVM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RADX (Radiopharm Theranostics Ltd)|ARTV (Artiva Biotherapeutics Inc.) - EV/EBITDA Multiple|Adlai Nortye Limited (ANL) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple VERU|TPST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xilio Therapeutics XLO|Total Company Value to Operating Income Before Depreciation Ratio Renovaro Biosciences (RENB)|MURA: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation KAPA (Kairos Pharma Ltd)|OKUR: EV/EBITDA Multiple|GDTC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Curis Inc.|Enterprise Value to Operating Income Before Depreciation APLM (Apollomics Corp)|EV/EBITDA Multiple THAR|Enterprise Value to EBITDA Ratio advanbiomed.com ADVB|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Genprex GNPX|Calidi Biotherapeutics Inc. (CLDI) - Company Value to EBITDA|SBFM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PPBT (purple-biotech.com)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization American Oncology Network Inc|Company Value to EBITDA BeiGene Ltd. BGNE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Checkpoint Therapeutics, Inc (CKPT)|ELEV (Elevation Oncology Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ICAD (iCAD)|EV/EBITDA Multiple Ikena Oncology Inc. IKNA|NTBL: Enterprise Value to EBITDA Ratio|Viracta Therapeutics - Enterprise Value to Operating Income Before Depreciation Ratio|MOR: EV/EBITDA Multiple|Company Value to EBITDA NAYA Biosciences Corp (NAYA)|AAPGV (Ascentage Pharma Group) - EV/EBITDA Multiple
